Navigation Links
Allos Therapeutics Initiates Study of RH1 in Patients with Advanced Solid Tumors or non-Hodgkin's Lymphoma
Date:11/12/2007

WESTMINSTER, Colo., Nov. 12 /PRNewswire-FirstCall/ -- Allos Therapeutics, Inc. (Nasdaq: ALTH) today announced the initiation of patient enrollment in a Phase 1, non-randomized, open-label, multi-center dose escalation study of the Company's targeted chemotherapeutic agent RH1 in patients with advanced solid tumors or non-Hodgkin's lymphoma (NHL).

"We are pleased to advance the development of this agent," said Pablo J. Cagnoni, M.D., Chief Medical Officer of Allos. "RH1 is a small molecule chemotherapeutic agent that is bioactivated by the enzyme DT-diaphorase (DTD), which is over-expressed in many tumors, including lung, colon, breast and liver tumors. We believe that because RH1 is bioactivated in the presence of DTD, it has the potential to preferentially target certain tumors while limiting the amount of toxicity to normal tissue."

In this study, patients with either advanced solid tumors or NHL will receive a 3-hour intravenous (IV) infusion of RH1 administered once every 21 days. Patients will receive starting doses of RH1 at 1.5 mg/m2, with dose escalation in subsequent cohorts based on toxicity. Up to 60 evaluable patients will be enrolled in the study with the objective of determining the maximum tolerated dose (MTD), recommended Phase 2 dose and safety profile of RH1 in this population. Three to six patients will be enrolled per cohort. An expanded cohort of up to 24 evaluable patients who have tumor types with a high likelihood of DTD over-expression will be recruited to explore possible markers of anticancer activity. D. Ross Camidge, M.D., Ph.D., Assistant Professor of Medical Oncology at the University of Colorado Cancer Center, will serve as the study chair.

Information regarding this s
'/>"/>

SOURCE Allos Therapeutics, Inc.
Copyright©2007 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. Allos Therapeutics Initiates Study of PDX in Patients with Cutaneous T-Cell Lymphoma
2. Interim Response and Safety Analyses Support Continuation of Allos Therapeutics Pivotal Phase 2 PROPEL Trial of PDX in Patients with Peripheral T-Cell Lymphoma
3. Vicus Therapeutics to Present at the 234th American Chemical Society National Meeting in Boston, MA
4. Amicus Therapeutics Announces Second Quarter 2007 Financial Results
5. TorreyPines Therapeutics Completes Patient Enrollment in Phase IIb Clinical Trial of Tezampanel for the Treatment of Acute Migraine Headache
6. CV Therapeutics Announces Eight Abstracts Accepted for Presentation at the European Society of Cardiology Congress 2007
7. Pharmacopeia Assists the World Health Organization in the Discovery of Novel Therapeutics for the Treatment of Malaria
8. Protalix BioTherapeutics Treats First Patient in Phase III Clinical Trial of prGCD
9. TorreyPines Therapeutics Initiates a Phase I Multiple Dose Clinical Trial of Tezampanel
10. TorreyPines Therapeutics Completes Phase I Multiple Dose Clinical Trial of NGX267, a Selective M1 Agonist for the Potential Treatment of Cognitive Impairment Associated with Schizophrenia
11. Cell Therapeutics, Inc. (CTI) Launches Phase III Study for Pixantrone in Relapsed Indolent Non-Hodgkins Lymphoma (NHL)
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/18/2014)... After 6 months of careful research ... - the new programme for the next Cool Chain & ... global Cool Chain series, has just been released! ... As the lines between supply chain, logistics, QA and purchasing ... is broad and yet specific, focused and yet accessible, inclusive ...
(Date:9/18/2014)...  Spring Bank Pharmaceuticals, Inc., a clinical-stage biopharmaceutical ... RNA viruses, today announced a research collaboration with ... testing of the Company,s lead compound, SB 9200, ... against which currently there are no effective antiviral ... proprietary Small Molecule Nucleic Acid Hybrid (SMNH) ...
(Date:9/18/2014)... ROCKVILLE, Md. , Sept. 18, 2014 ... a biotechnology company with fully integrated commercial and drug ... oncology, and CASI Pharmaceuticals, Inc. (Nasdaq: CASI ... and commercialization of innovative therapeutics addressing cancer and other ... primary focus on China , announce ...
Breaking Medicine Technology:Europe's Biggest and Longest-Running Gathering of Life Sciences Logistics, Supply Chain & QA Professionals 2Spring Bank Pharmaceuticals Announces NIH Collaboration for Testing of SB 9200 Against Multiple Viral Pathogens 2Spectrum Pharmaceuticals Out-Licenses Rights for Greater China to CASI Pharmaceuticals for Three of Its Drugs 2Spectrum Pharmaceuticals Out-Licenses Rights for Greater China to CASI Pharmaceuticals for Three of Its Drugs 3Spectrum Pharmaceuticals Out-Licenses Rights for Greater China to CASI Pharmaceuticals for Three of Its Drugs 4Spectrum Pharmaceuticals Out-Licenses Rights for Greater China to CASI Pharmaceuticals for Three of Its Drugs 5Spectrum Pharmaceuticals Out-Licenses Rights for Greater China to CASI Pharmaceuticals for Three of Its Drugs 6Spectrum Pharmaceuticals Out-Licenses Rights for Greater China to CASI Pharmaceuticals for Three of Its Drugs 7Spectrum Pharmaceuticals Out-Licenses Rights for Greater China to CASI Pharmaceuticals for Three of Its Drugs 8Spectrum Pharmaceuticals Out-Licenses Rights for Greater China to CASI Pharmaceuticals for Three of Its Drugs 9Spectrum Pharmaceuticals Out-Licenses Rights for Greater China to CASI Pharmaceuticals for Three of Its Drugs 10
(Date:9/18/2014)... New York, New York (PRWEB) September 18, 2014 ... dozen Xarelto lawsuits ( http://www.xareltolawsuitcenter.com ) currently pending ... attempting to have all claims filed on behalf ... According to motions filed on September 11th, the ... and other claims contained in the lawsuits have ...
(Date:9/18/2014)... Kent, WA Chiropractor Danene Saggau and the ... that Dawn Kelly has agreed to become the new Office ... to Ms. Kelly expanding her role within the practice, noting ... key contributor. “ Dawn Kelly brings to the clinic ... that will allow me to focus on the patient ...
(Date:9/18/2014)... Dr. David A. F. Ellis is a Board ... Facial Plastic and Reconstructive Surgery and a Professor at ... Plastic Surgery. He is recognized around the world ... Dr. Ellis will be presenting on numerous injectable topics. ... techniques and various treatments for complications associated with injectable ...
(Date:9/18/2014)... September 18, 2014 Alexandria, VA — ... today that 10 more communities have joined the growing ... health department accreditation. The decisions bring the number of ... 54. PHAB is the non-profit organization that administers the ... and protect the health of the public by advancing ...
(Date:9/18/2014)... (HealthDay News) -- Exposure to diverse communities may boost ... Hearing different languages in the park or supermarket ... from people who are different from them, researchers found. ... are often biased against interacting with and learning from ... a University of Chicago psychology professor, said in a ...
Breaking Medicine News(10 mins):Health News:Xarelto Lawsuit Defendants Seek to Have Pennsylvania Claims Filed by Out-of-State Plaintiffs Dismissed, Bernstein Liebhard LLP Reports 2Health News:Xarelto Lawsuit Defendants Seek to Have Pennsylvania Claims Filed by Out-of-State Plaintiffs Dismissed, Bernstein Liebhard LLP Reports 3Health News:Lake Meridian Chiropractic of Kent, WA Announces that Dawn Kelly Has Been Promoted to the Position of Office Manager 2Health News:Dr. David A. F. Ellis Has Been Invited to Speak at a Conference of the American Academy of Facial Plastic and Reconstructive Surgery in Orlando, Florida 2Health News:Ten More Communities Reaping Benefits of National Accreditation 2Health News:Ten More Communities Reaping Benefits of National Accreditation 3Health News:Ten More Communities Reaping Benefits of National Accreditation 4Health News:Study: Exposure to Diversity Might Boost Baby's Social Skills 2
... , , , INDIANAPOLIS, ... been named by Adventist Health System as its exclusive clearinghouse ... utilize RealMed,s portal-based clearinghouse/Revenue Cycle Management Services to improve Adventist ... , , (Logo: ...
... , , , ... development-stage pharmaceutical company discovering and developing novel RNA interference ... Vice President, Pharmaceutical Development, will participate in multiple roles ... The conference will take place August 3-5, 2009 in ...
... , , HATBORO, Pa., ... IFLG ), a leading technology provider of enterprise ... the introduction of a new mobility offering for healthcare providers, ... solution that enables medical professionals to access critical patient information ...
... , , , ... August 3 Zogenix, Inc. ("Zogenix"), a privately held ... today their exclusive co-promotion agreement for Sumavel DosePro (sumatriptan ... approval in July 2009 and is a first-of-its-kind needle-free ...
... skills increase the risk of trouble, expert says, , MONDAY, ... ramping up physical education programs to battle the childhood obesity ... has risen dramatically, Ohio State University researchers report. , ... injuries related to physical education (PE) increased 150 percent -- ...
... published in the August issue of The Journal of ... an important tool for depicting the extent of neuroblastoma in ... the disease. Neuroblastoma accounts for six to ten percent of ... of cancer deaths in children. Accurately identifying where in the ...
Cached Medicine News:Health News:RealMed Named Exclusive Medical Claims Clearinghouse for Physicians by Adventist Health System 2Health News:RealMed Named Exclusive Medical Claims Clearinghouse for Physicians by Adventist Health System 3Health News:Quark Pharmaceuticals to Participate in IBC's Oligonucleotide Therapeutics: From Concept to Implementation Conference 2Health News:Quark Pharmaceuticals to Participate in IBC's Oligonucleotide Therapeutics: From Concept to Implementation Conference 3Health News:New InfoLogix M24 Mobile Clinical Assistant Will Enable Hospitals to Access Electronic Medical Records (EMR) Directly at the Point of Care 2Health News:New InfoLogix M24 Mobile Clinical Assistant Will Enable Hospitals to Access Electronic Medical Records (EMR) Directly at the Point of Care 3Health News:Zogenix and Astellas Enter Exclusive Co-Promotion Agreement in the US for Newly Approved Sumavel(TM) DosePro(TM) 2Health News:Zogenix and Astellas Enter Exclusive Co-Promotion Agreement in the US for Newly Approved Sumavel(TM) DosePro(TM) 3Health News:Zogenix and Astellas Enter Exclusive Co-Promotion Agreement in the US for Newly Approved Sumavel(TM) DosePro(TM) 4Health News:Gym Class Injuries Up 150 Percent 2Health News:Gym Class Injuries Up 150 Percent 3Health News:PET can help guide treatment decisions for a common pediatric cancer 2
... This functional brace is designed for the ... and fibula. The preformed design provides post ... removal of internal or external fixation. The ... and below the fracture site, increasing vascularity ...
... Brace features a multi-axial hinge that duplicates ... altering kinematics. The infinite degree of adjustment ... and extension control of the knee. , ... tibia in correct anatomical alignment. The precision ...
... is a revolutionary cast replacement system for ... leg and foot. , ,A self-adjusting ... and in conjunction with a rigid lattice ... time of fracture or rupture healing can ...
... the constant demands of mobilizing patients quickly. ... necessary to fit bilateral KAFO's.,The complete kit ... knee joints , 4 Copolymer thigh support ... bands , Ortho-wick™ Padding for thigh , ...
Medicine Products: